A troubling drug pairing
Pfizer's plan to market a promising new cholesterol drug only in combination with one of its existing products may well make sense as a business decision. But it will limit the flexibility of doctors
Pfizer's plan to market a promising new cholesterol drug only in combination with one of its existing products may well make sense as a business decision. But it will limit the flexibility of doctors